Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 4 Carcinoma, Non-Small-Cell Lung 4 Breast Neoplasms 3 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Mesothelioma, Malignant 1 Mesothelioma 1 Gastrointestinal Neoplasms 1 Fanconi Anemia, Complementation Group D1 1

Interventions

Cisplatin 57 Pemetrexed 46 pembrolizumab 18 Nivolumab 15 Carboplatin 15 Gemcitabine 14 Cyclophosphamide 13 Radiotherapy 10 Drug Therapy 9 atezolizumab 8 Platinum 7 Ipilimumab 7 Doxorubicin 7 durvalumab 6 1,2-diaminocyclohexaneplatinum II citrate 6 tremelimumab 5 sodium thiosulfate 5 Vinorelbine 5 Radiotherapy, Intensity-Modulated 5 Interleukin-2 5 Chemotherapy, Adjuvant 5 Cerebral Decortication 5 sargramostim 4 fludarabine 4 defactinib 4 aldesleukin 4 tumor necrosis factor-alpha, CNGRC fusion protein, human 3 cediranib 3 Photochemotherapy 3 Neoadjuvant Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma, Malignant × talazoparib × Thoracic × Clear all

NCT04462809 2020-07-09

TALAMESO

Hospices Civils de Lyon

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡